AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 221 min read$KMTS

Umberger Traci S sold $2.7M of KMTS

Umberger Traci S (See Remarks) sold 100,000 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $27.18 ($27.15–$28.09, $2.72M total) across 2 trades on 2026-10-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Umberger Traci S
Published Oct 22, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The filing confirms a $2.7 M sale by an officer, which may be interpreted as a neutral signal by the market.

02

Market read

A modest insider sell; limited immediate trading relevance.

03

What to watch

The 10b5‑1 plan suggests pre‑planned execution, reducing the informational value of the trade.

Relevance 5/10Novelty 4/10Timing: today

Background

SEC Form 4 disclosures provide the first public record of insider transactions.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Form 4 filing shows officer Traci S. Umberger sold 100,000 shares for $2.7 M via a 10b5‑1 plan.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

A $2.7 M sale by an officer is material enough to be noted but not large enough to drive a significant move.

Market effects

Sector

Minimal impact on the broader medical device sector.

Regional

Limited to investors tracking KMTS.

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine liquidity event and not indicative of negative fundamentals.

Key entities

  • company
    Kestrel Medical Technologies, Ltd.

    Medical device manufacturer listed on Nasdaq under KMTS.

  • person
    Traci S. Umberger

    Officer and director of KMTS who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KMTS insider trading history →

Related articles

OCT 20
$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

investing.com2 min
SEP 16
$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.

tipranks.com3 min
SEP 15
$KMTSMed

Kestra (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue of $31.0M, up 60% YoY, and raised full-year guidance to $141M. Gross margin increased to 56.5%, driven by volume leverage and cost improvements. The company invested heavily in R&D and commercial expansion, resulting in a GAAP net loss of $44.1M. Management highlighted market share gains and expanded payer coverage for non-ischemic patients.

aol.com2 min
SEP 15
$KMTSMedAI 8/10

Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60%

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.

yahoo.com3 min